Rick, you have pointed out a couple things
regarding Onyx recently on other threads...
I appreciate you taking the time to help lead
me to the right questions, but I could use a
couple of clarifications--
You once posed to Larry on the tfif thread (#330)
if there was evidence that the results are due to
p53 itself?
I never did understand what you meant by that.
And then, more recently, you posed to me the question--
Does the virus selectively replicate in the tumor?
And of course, to me, it just looks like the answer
is right there in front of me--and even in the message
you just posted.
But I thought that was the point to onyx-015 all
along? "The specific modification of the virus prevents
it from replicating efficiently in normal cells."
--but that is just off the company website, old news
I guess, so I must be missing something?
ONYX-015 preferentially targets p53 mutant tumors
whereas chemotherapy is often more effective in tumor
cells with functional p53.
(by the way...I understand MOGN is not about p53, and
that Onyx-015 is a totally different animal...naturally
keeping an eye on the gene therapy stuff as well
had a part in leading me to Onyx.) |
